Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3158-3163

  Dumstorf, Chad A ^b   Konicek, Bruce W ^b   McNulty, Ann M ^b   Parsons, Stephen H ^b   Furic, Luc ^b   Sonenberg, Nahum ^b   Graff, Jeremy R ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENZASTAURIN; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; CARRIER PROTEIN; EIF4EBP1 PROTEIN, MOUSE; INDOLE DERIVATIVE; INITIATION FACTOR 4F; PHOSPHOPROTEIN;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG PROTEIN BINDING; EMBRYO; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ANIMAL; APOPTOSIS; DRUG EFFECT; DRUG SCREENING; GENE INACTIVATION; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; EUKARYOTIC INITIATION FACTOR-4F; GENE KNOCKOUT TECHNIQUES; HUMANS; INDOLES; MICE; MICE, KNOCKOUT; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 78650434193     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0413     Document Type: Article

References (33)

1. Graff JR, McNulty AM, Hanna KR, et al.The protein kinase C beta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9.
2. Tekle C, Giovannetti E, Sigmond J, et al.Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in nonsmall cell lung cancer cells. Br J Cancer 2008;99:750-9.
3. Haghighat A, Mader S, Pause A, Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: Competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J 1995;14:5701-9.
4. Mader S, Lee H, Pause A, Sonenberg N. The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. Mol Cell Biol 1999;15;4990-7.
5. Gingras AC, Raught B, Gygi SP, et al.Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001;15:2852-64.
6. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E-from translation to transformation. Oncogene 2004;23(18):3172-9.
7. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189-99.
8. Hsieh AC, Costa M, Zollo O, et al.Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cells 2010;17:249-61.
9. Graff JR, Konicek BW, Lynch RL, et al.eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009;69:3866-73.
10. Wang R, Geng J, Wang JH, et al.Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. Lung Cancer 2009;66:237-44.
11. Chen CN, Hsieh FJ, Cheng YM, Lee PH, Chang KJ. Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol 2004;86:22-7.
12. Li BD, Liu L, Dawson M, De Benedetti A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 1997;79:2385-90.
13. Sorrells DL Jr., Ghali GE, De Benedetti A, Nathan CO, Li BD. Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers. J Oral Maxillofac Surg 1999;57:294-9.
14. Petroulakis E, Parsyan A, Dowling RJ, et al.p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell 2009;16:439-46.
15. Kim YY, Von WL, Larsson O, et al.Eukaryotic initiation factor 4E binding protein family of proteins: Sentinels at a translational control checkpoint in lung tumor defense. Cancer Res 2009;69:8455-62.
16. Avdulov S, Li S, Michalek V, et al.Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 2004;5:553-63.
17. Rousseau D, Gingras AC, Pause A, Sonenberg N. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 1996;13:2415-20.
18. Jacobson BA, Alter MD, Kratzke MG, et al.Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 2006;66:4256-62.
19. Rojo F, Najera L, Lirola J, et al.4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007;13:81-9.
20. Castellvi J, Garcia A, Rojo F, et al.Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006;107:1801-11.
21. Graff JR, Konicek BW, Vincent TM, et al.Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007;117:2638-48.
22. Assouline S, Culjkovic B, Cocolakis E, et al.Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): A proof-of-principle clinical trial with ribavirin. Blood 2009;114:257-60.
23. Moerke NJ, Aktas H, Chen H, et al.Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 2007;128:257-67.
24. She QB, Halilovic E, Ye Q, et al.4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010;18:39-51.
25. Le BO, Petroulakis E, Paglialunga S, et al.Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 2007;117:387-96.
26. Robertson MJ, Kahl BS, Vose JM, et al.Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6.
27. Carducci MA, Musib L, Kies MS, et al.Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-9.
28. Rieger J, Lemke D, Maurer G, et al.Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem 2008;106:2436-48.
29. Querfeld C, Rizvi MA, Kuzel TM, et al.The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126:1641-7.
30. Lee KW, Kim SG, Kim HP, et al.Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 2008;68:1916-26.
31. Rizvi MA, Ghias K, Davies KM, et al.Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783-9.
32. Neri A, Marmiroli S, Tassone P, et al.The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008;49: 1374-83.
33. Moreau AS, Jia X, Ngo HT, et al.Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007;109:4964-72.